---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028343"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:41:44.422560+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BriaCell Quadruples PFS to 9.1 Months in Top Responder Metastatic Breast Cancer Patient

## Summary
- PFS extended to 9.1 months in top responder patient, quadruple historical controls (1.7-2.3 months).
- Patient had failed 8 prior regimens including ADC therapy; continues on BriaCell treatment.
- Brain lesion undetectable, orbital lesion shrinking; tumor markers markedly decreased from pre-treatment.
- Phase 2 study of Bria-IMT regimen plus immune checkpoint inhibitor in metastatic breast cancer.
- Patient remains alive; company plans to replicate results in ongoing Phase 3 study.

## SEC filing metadata
- accession: 0001493152-24-028343
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315224028343/0001493152-24-028343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315224028343/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028343
- JSON: https://secwatch.observer/filing/0001493152-24-028343.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.